| Objective: To evaluate the curative effect of bevacizumab treatment for glioma objectively and systematically via a meta-analysis,and to provide a reference for the diagnosis,treatment and future research of glioma patients.Methods: Searching Pub Med,EMBASE,Cochrane Library,and Web of Science for clinical studies of bevacizumab treatment for glioma published before December 2017.After screening the literature,the relevant data in the selected literature were extracted and processed using the Review Manager 5.3Results: According to the exclusion and included criteria,the final inclusion of four articles,including a total of 1815 patients,of which 888 patients in the experimental group received temozolomide,radiotherapy and bevacizumab,and 927 patients in the control group received temozolomide and radiotherapy.The result of the meta-analysis demonstrated that the progression-free survival(PFS)of the experimental group was prolonged(HR=0.72,95%CI 为 0.64-0.79,P<0.00001),compared with the control group,but there was no statistical significance between the two groups in overall survival(OS,HR=1.02,95%CI 为 0.81-1.29,P=0.85).Subgroup analyses showed that the timing of bevacizumab use and the timing of radiotherapy did not lead to data heterogeneity.The funnel plot shows there is not apparent publication bias between the groups of data.Bevacizumab may increase the incidence of adverse reactions,but bevacizumab monotherapy remains well tolerated.Conclusion: Based on the analysis of the current literatures in this study,bevacizumab can prolong the progression-free survival of patients with gliomas,but its effect on prolonging the overall survival of glioma patients is not clear,so it is still necessary to improve the treatment program. |
PDF Full Text Request